Instil Bio, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
TIL$6.35-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive · Accumulated Deficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount · (Loss) | ||||||
| Balance - December 31, 2024 | 6,525,887 | $— | $824,780 | $(228) | $(655,116) | $169,436 |
| Issuance of common stock upon exercise of stock options | 33,040 | — | 404 | — | — | 404 |
| Stock-based compensation | — | — | 3,495 | — | — | 3,495 |
| Net loss | — | — | — | — | (28,200) | (28,200) |
| Other comprehensive loss | — | — | — | (223) | — | (223) |
| Balance - March 31, 2025 | 6,558,927 | — | 828,679 | (451) | (683,316) | 144,912 |
| Issuance of common stock upon exercise of stock options | 5,952 | — | 71 | — | — | 71 |
| Issuance of common stock in at-the-market offering, net of $0.3 million in issuance costs | 185,837 | — | 6,611 | — | — | 6,611 |
| Stock-based compensation | — | — | 1,824 | — | — | 1,824 |
| Net loss | — | — | — | — | (21,394) | (21,394) |
| Other comprehensive loss | — | — | — | (354) | — | (354) |
| Balance - June 30, 2025 | 6,750,716 | — | 837,185 | (805) | (704,710) | 131,670 |
| Issuance of common stock upon exercise of stock options | 31,260 | — | 378 | — | — | 378 |
| Stock-based compensation | — | — | 1,768 | — | — | 1,768 |
| Net loss | — | — | — | — | (13,587) | (13,587) |
| Other comprehensive income | — | — | — | 193 | — | 193 |
| Balance - September 30, 2025 | 6,781,976 | $— | $839,331 | $(612) | $(718,297) | $120,422 |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (CONTINUED)
(in thousands, except share amounts)
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive · Accumulated Deficit · Total Stockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · (Loss) | |||||||
| Balance - December 31, 2023 | 6,503,913 | $— | $807,158 | $(348) | $(580,981) | $225,829 | |
| Stock-based compensation | — | — | 4,515 | — | — | 4,515 | |
| Net loss | — | — | — | — | (24,302) | (24,302) | |
| Other comprehensive loss | — | — | — | (215) | — | (215) | |
| Balance - March 31, 2024 | 6,503,913 | — | 811,673 | (563) | (605,283) | 205,827 | |
| Stock-based compensation | — | — | 4,173 | — | — | 4,173 | |
| Net loss | — | — | — | — | (14,917) | (14,917) | |
| Other comprehensive loss | — | — | — | (64) | — | (64) | |
| Balance - June 30, 2024 | 6,503,913 | — | 815,846 | (627) | (620,200) | 195,019 | |
| Shares of common stock issued in connection with incentive stock plan | 21,353 | 159 | 159 | ||||
| Stock-based compensation | — | — | 4,068 | — | — | 4,068 | |
| Net loss | — | — | — | — | (23,021) | (23,021) | |
| Other comprehensive income | — | — | — | 107 | — | 107 | |
| Balance - September 30, 2024 | 6,525,266 | $— | $820,073 | $(520) | $(643,221) | $176,332 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.